MDR-1339
CAS No. : 1018946-38-7
(Synonyms: DWK-1339)
| Size | Price | Stock |
|---|---|---|
| 5mg | $155 | In-stock |
| 10mg | $244 | In-stock |
| 25mg | $488 | In-stock |
| 50mg | $733 | In-stock |
| 100mg | $1100 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-14503 |
| M.Wt: | 326.39 |
| Formula: | C20H22O4 |
| Purity: | >98 % |
| Solubility: | DMSO : 50 mg/mL (ultrasonic) |
MDR-1339 (DWK-1339) is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease. IC50 & Target: Amyloid-β[1] In Vitro: MDR-1339 is an Aβ-aggregation inhibitor, and shows no significant inhibition a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50, 31.4 μM). MDR-1339 (3.1-50 μM) dose-dependently blocks the formation of Aβ aggregates, and disaggregates Aβ fibrils. MDR-1339 (1.5-10 μM) also protects cells from this Aβ-induced toxicity[1]. In Vivo: MDR-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores the passive avoidance responses in mice models of Alzheimer's disease (AD), with an ED50 of 0.19 mg/kg. MDR-1339 (30 and 100 mg/kg, p.o. daily for 8 weeks) significantly improves spontaneous alternation, and reduces the Aβ1-40 and Aβ1-42 levels in APP/PS1 mice[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- MDR-1339
- Cat. No.:
- HY-14503
- Quantity:
Your information is safe with us.